Cardiovascular Disease in Adult and Pediatric HIV/AIDS

• Published in: Journal of the American College of Cardiology Vol. 54; no. 13; pp. 1185 - 1188
• Main Authors: McDonald, Cheryl L., MD, Kaltman, Jonathan R., MD
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 22-09-2009; Elsevier Limited
• Subjects: Acquired immune deficiency syndrome; Adult; AIDS; Anti-HIV Agents - therapeutic use; Antiretroviral drugs; Antiretroviral Therapy, Highly Active; Cardiology; Cardiovascular; cardiovascular disease; Cardiovascular Diseases - etiology; Child; Cholesterol; Drug therapy; drug toxicity; dyslipidemia; highly active antiretroviral therapy; HIV; HIV Infections - complications; HIV Infections - drug therapy; HIV/AIDS; Human immunodeficiency virus; Humans; Internal Medicine; Studies; HIV/AIDS; cardiovascular disease; ART; zidovudine; antiretroviral therapy; National Heart, Lung, and Blood Institute; PPH; LV; primary pulmonary hypertension; CVD; human immunodeficiency virus/acquired immunodeficiency syndrome; NHLBI; drug toxicity; PAH; highly active antiretroviral therapy; AZT; left ventricular; dyslipidemia; pulmonary arterial hypertension; HAART
• ISSN: 0735-1097; 1558-3597
• DOI: 10.1016/j.jacc.2009.05.055

Since it was first recognized clinically in 1981, human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) has gone from a fatal syndrome to a chronic disease in persons receiving highly active antiretroviral therapy (HAART). Patients with HIV-PAH have worse survival than do HIV-infected patients without PAH and often die from conditions related to the pulmonary hypertension, not the HIV infection per se. [...]prompt diagnosis and initiation of specific therapy such as a prostacyclin (epoprostenol) or the dual endothelin receptor antagonist bosentan is crucial (15).